Griffin Report 07Oct14, page-55

1. We don't have a supply agreement, which is sorta weird with an impending drug launch.

2. How much manufacturing capacity would we need to meet a big drug launch in a years time (in addition to all our other commitments for Lovenox and Hikma)? I'm guessing our current PFS manufacturing capacity (including lines not yet certified) is no more than 120 million units per annum. That's based on our original 60 million unit Unifill manufacturing line costing about $12 million. We spent $12 million on capex in the year to June 2014 so that would give us another 60 million units (though some of that capex would have also been spent on non-PFS lines, clean room changes, those big air conditioner units, etc). Also, those 120 million units would be divided between Unifil, Finesse and Nexus.

3. If its secret squirrel and we do have the Alirocumab PFS contract, where are the milestone payments that we should have booked in our accounts over the past year or so? A substantial contract like this would involve some lumpy payments that we would have noticed.